The global statin market is currently witnessing stable growth.
Statin is a lipid-lowering medication, an agent that is consumed by patients to reduce their blood cholesterol levels. Atorvastatin, rosuvastatin, lovastatin and simvastatin are the most common types of statins available in the market. They aid in preventing the instances of atherosclerosis and heart attacks and have significant anti-inflammatory and plaque-stabilizing effects. These drugs also aid in minimizing vascular inflammation and oxidative stress in the body. Besides this, statin interferes with the production of enzymes that are crucial for the liver to produce cholesterol, thus aiding in lowering the overall blood cholesterol levels in the body.
The increasing prevalence of hypercholesterolemia across the globe is among the key factors driving the growth of the market. This disorder is highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, obesity and cardiovascular diseases (CVDs), which is facilitating product adoption across both the developed and emerging nations. Furthermore, increasing consumer preference for over-the-counter (OTC) drugs is another factor contributing to the market growth. In comparison to brand name drugs, OTC variants are usually more affordable. Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients and significantly reducing the risk of CVDs occurrence. Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market further.
This latest report provides a deep insight into the global statin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the statin industry in any manner.
Breakup by Type: Synthetic Statins Natural Statins
Breakup by Therapeutic Area: Cardiovascular Disorders Obesity Inflammatory Disorders Others
Breakup by Drug Class: Atorvastatin Fluvastatin Lovastatin Pravastatin Simvastatin Others
Breakup by Application: Dyslipidemia Others
Breakup by Distribution: Hospitals Clinics Others
Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa
Competitive Landscape: The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Biocon, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, etc.
Key Questions Answered in This Report: How has the global statin market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the therapeutic area? What is the breakup of the market based on the drug class? What is the breakup of the market based on the application? What is the breakup of the market based on the distribution? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the market? What is the structure of the global statin market and who are the key players? What is the degree of competition in the market?
Our reports have been used by over 10K customers, including:
Abstract:
- Global Peripheral Arterial Disease (PAD) Therapeutics Market to Reach $1.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Peripheral Arterial Disease (PAD) Therapeutics estimated at US$776.4 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
267 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Acute Heart Failure (AHF) Therapeutics Market to Reach $1.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$372.9 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of...
Left Ventricular Dysfunction (Cardiovascular) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Drugs in Development, 2021, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left...
Hepatic Encephalopathy (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic...
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
Arteriosclerosis (Cardiovascular) - Drugs in Development, 2021 Summary Arteriosclerosis (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Arteriosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arteriosclerosis,...
Colon Carcinoma (Oncology) - Drugs in Development, 2021 Summary Colon Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete...
Infectious Diarrhea (Gastrointestinal) - Drugs in Development, 2021 Summary Infectious Diarrhea (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Infectious Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Digestive System Disorder
Gastrointestinal Drug
Therapy
Research And Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.